SEONGNAM, South Korea & CAMBRIDGE, Mass. (BUSINESS WIRE) Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the.
Bridge Biotherapeutics to Present Tuesday at the BIO International Convention streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer,.
/PRNewswire/ Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation,.